DMP (Morocco)

DMP (the Direction du Médicament et de la Pharmacie) is the Kingdom of Morocco's national regulatory authority responsible for the regulation of human medicines + biologicals + vaccines + medical devices + IVDs + pharmacy practice + cosmetics + drugs of abuse + pharmaceutical-industry oversight. DMP operates as a Directorate within the Ministry of Health and Social Protection (Ministère de la Santé et de la Protection Sociale) — distinctively a Ministry Directorate rather than autonomous agency, similar in institutional structure to Peru DIGEMID + France ANSM's pre-1993 status (ANSM became autonomous with AFSSAPS reform in 1993 + has since reformed twice). DMP's Ministry-Directorate status reflects Morocco's centralised francophone administrative tradition + provides direct Ministerial accountability + budget integration + simultaneously constrains DMP's institutional autonomy + fee-retention compared to autonomous regulators.

DMP traces its origins to the Dahir 1-58-295 of 12 April 1959 (one of the earliest post-independence Moroccan pharmaceutical regulations, issued shortly after Moroccan independence in 1956) + was extensively reformed by Law 17-04 of 22 November 2006 (Code du Médicament et de la Pharmacie — the current organic Pharmaceutical Code, signed into Royal Dahir 1-06-151). Law 17-04 modernised Moroccan pharmaceutical regulation to align with EU + WHO frameworks + introduced comprehensive Marketing Authorisation (Autorisation de Mise sur le Marché — AMM) + GMP + pharmacovigilance + clinical-trial frameworks + provided foundation for Moroccan generic-medicines industry growth (Morocco has substantial domestic pharmaceutical manufacturing capacity with ~40 manufacturers including Sothema, Cooper Pharma, Sanofi-Aventis Maroc, Laprophan, Pharma 5).

DMP's organisational structure includes:

• Directeur du Médicament et de la Pharmacie — chief executive appointed by the Minister of Health with Royal endorsement; serves at the discretion of the Crown.
• Division de la Pharmacie — pharmacy practice + pharmacy premises licensing + pharmaceutical-establishment authorisation + pharmaceutical-industry oversight.
• Division du Laboratoire National de Contrôle des Médicaments (LNCM) — WHO-prequalified pharmaceutical QC laboratory (since 2016) + ISO/IEC 17025 accredited + PAHO + AFRO Reference Regional Laboratory.
• Division de l'Inspection — Moroccan + foreign manufacturer + distributor + pharmacy GMP/GDP/GPP inspections.
• Division de l'Évaluation des Médicaments + AMM (Autorisation de Mise sur le Marché) — drug + biological + vaccine + biosimilar + biotechnology + generic-medicine registration via Marketing Authorisation procedure.
• Division des Dispositifs Médicaux + Cosmétiques — medical-device + IVD + cosmetic registration + post-market materiovigilance + cosmetovigilance.
• Division de la Pharmacovigilance — Centre Anti-Poison et de Pharmacovigilance du Maroc (CAPM, Rabat) coordination + adverse-event surveillance + WHO PIDM coordination.
• Division de la Réglementation et des Affaires Internationales — international cooperation + WHO + AMRH + AMA + EU + Arab League + UfM coordination.
• Service des Affaires Économiques + Tarification — pharmaceutical-price regulation + reimbursement coordination with AMO (Assurance Maladie Obligatoire) + CNSS + CNOPS.
• Commission Nationale Consultative des Autorisations de Mise sur le Marché (CNCAMM) — advisory commission with academic + medical + pharmaceutical industry + civil society representation issuing scientific opinions on AMM applications.
• Centre Anti-Poison et de Pharmacovigilance du Maroc (CAPM) — Rabat-based national pharmacovigilance + toxicovigilance + anti-poison centre operating under DMP coordination.
• Network of regional pharmacy + drugs-of-abuse inspectors coordinated through Direction Régionale de la Santé in each of Morocco's 12 administrative regions.

DMP is distinct from + complementary to: the Ministry of Health and Social Protection broader Directorates (Direction de la Population, Direction Régionale de la Santé, Direction des Soins de Santé Primaires); the Ordre National des Pharmaciens du Maroc (Order of Pharmacists, pharmacist professional body); the ONSSA (Office National de Sécurité Sanitaire des produits Alimentaires, food safety + veterinary medicines + animal-origin foods); the ANRA (Agence Nationale de Régulation Avicole, poultry-sector regulation); the IMANOR (Institut Marocain de Normalisation, voluntary standards); the FMIIP (Fédération Marocaine de l'Industrie et de l'Innovation Pharmaceutique, the largest Moroccan pharmaceutical industry association representing ~40 manufacturers); + the AMM (Association Marocaine de l'Industrie Pharmaceutique, industry association). DMP's institutional environment is characterised by a substantial Moroccan domestic pharmaceutical manufacturing sector (~70% of consumed medicines manufactured in Morocco), substantial French + EU regulatory tradition + alignment, + emerging Maghreb + sub-Saharan African market export orientation.

Legal foundations are Dahir 1-58-295 of 12 April 1959 (original pharmaceutical regulation); Law 17-04 of 22 November 2006 + Dahir 1-06-151 (Code du Médicament et de la Pharmacie — current organic Pharmaceutical Code); Decree 2-12-198 of 21 December 2012 + DMP Arrêtés (current AMM + GMP + pharmacovigilance + clinical-trial implementation decrees); Law 84-12 of 17 January 2014 (medical devices framework); Loi 06-99 of 5 June 2000 + Decree 2-07-1228 (pharmacy practice + pharmacy premises licensing); Dahir 1-73-282 of 24 May 1974 (controlled substances + narcotics + psychotropics framework); Law 65-00 of 3 October 2002 (cosmetics framework substantively aligned with EU Cosmetics Regulation); + a substantial body of DMP Arrêtés + Circulaires + Notes Techniques. Moroccan pharmaceutical regulation operates substantively in French (administrative + scientific language) with Arabic (official + Constitution language) + selective Amazigh/Tamazight (Constitutional co-official language since 2011) labelling requirements.

DMP is a WHO Listed Authority candidate + an active WHO Prequalification Collaborative Registration Procedure (CRP) participating authority + an active AMRH (African Medicines Regulatory Harmonisation) co-Reference Authority alongside SAHPRA + Ghana FDA + Kenya PPB + Tanzania TMDA + Uganda NDA + Rwanda FDA + Nigeria NAFDAC + Egyptian EDA + Ethiopia EFDA + an AMA (African Medicines Agency) Technical Committee participant + a Union for the Mediterranean (UfM) regulatory cooperation partner + an active League of Arab States Council of Arab Ministers of Health pharmaceutical-harmonisation participant. DMP holds substantial cooperation arrangements with EMA + ANSM France (historic Francophone alignment) + AEMPS Spain + AIFA Italy + PEI Germany + ANSM Tunisia + ANPP Algeria + AMA-positioned for full Continental African coordination.

Moroccan pharmaceutical regulation operates under a layered framework of Dahirs + Laws + Decrees + DMP Arrêtés + Notes Techniques:

• Dahir 1-58-295 of 12 April 1959 — original pharmaceutical regulation; foundational text.
• Law 17-04 of 22 November 2006 + Dahir 1-06-151 — Code du Médicament et de la Pharmacie; current organic Pharmaceutical Code.
• Decree 2-12-198 of 21 December 2012 — implementing AMM + GMP + pharmacovigilance + clinical-trial frameworks.
• Law 84-12 of 17 January 2014 — medical devices framework with Class I-III risk-based classification substantively aligned with EU MDR predecessor + GHTF/IMDRF.
• DMP Bonnes Pratiques de Fabrication (BPF) — Moroccan GMP framework substantively aligned with PIC/S GMP Guide + EU GMP + ICH Q7 + WHO TRS 986 Annex 2.
• DMP Bonnes Pratiques de Distribution (BPD) — Moroccan GDP framework substantively aligned with WHO + EU GDP.
• DMP Bonnes Pratiques Cliniques (BPC) — Moroccan GCP framework substantively aligned with ICH E6(R2).
• DMP Bonnes Pratiques de Pharmacovigilance (BPPv) — Moroccan pharmacovigilance framework substantively aligned with ICH E2 + EU GVP.
• Loi 06-99 + Decree 2-07-1228 — pharmacy practice + pharmacy premises licensing + pharmaceutical-establishment authorisation.
• Dahir 1-73-282 of 24 May 1974 — controlled substances + narcotics + psychotropics framework substantively aligned with UN Single Convention 1961 + Conventions 1971 + 1988.
• Law 65-00 of 3 October 2002 — Moroccan cosmetics framework substantively aligned with EU Cosmetics Regulation including INCI ingredient listing + safety substantiation.
• Code Pharmaceutique Marocain — Moroccan Pharmaceutical Codex; recognises European Pharmacopoeia + USP + BP + Moroccan Pharmacopoeia monographs.
• AMM Variations + Renewal Arrêtés — variations classification + procedures + 5-year AMM renewal framework.
• Decree 2-19-228 — recent updates to AMM + clinical-trial + biosimilar frameworks.

LNCM (the Laboratoire National de Contrôle des Médicaments) is DMP's central pharmaceutical quality-control laboratory in Rabat + holds WHO Prequalification of Quality Control Laboratories (WHO PQ-Lab) status since 2016 — one of the few WHO-prequalified pharmaceutical QC laboratories in Africa + the Mediterranean basin. LNCM joined a small group including South Africa NCL + Ethiopia NFBMQCL + Tanzania NCQAL + Egypt EDA NODCAR + selected African Pharmacopoeia + WHO Collaborating Centres. LNCM WHO PQ-Lab designation provides Morocco with direct regulatory laboratory capacity + supports WHO PQ + DMP regulatory testing + Global Fund + Gavi + UNICEF procurement + AMRH + AMA reliance frameworks.

• WHO Prequalification of Quality Control Laboratories Status — LNCM holds WHO PQ-Lab status since 2016; provides Morocco with WHO-recognised pharmaceutical QC capacity for WHO PQ + DMP regulatory testing + Global Fund + Gavi + UNICEF procurement support.
• ISO/IEC 17025 Accreditation — LNCM is ISO/IEC 17025 accredited (SEMAC — Service Marocain d'Accréditation) across multiple testing scopes including pharmaceutical chemical + microbiological + biological testing.
• AMRH + AFRO Regional Reference Laboratory — LNCM serves AMRH-coordinated regional reference-laboratory functions for sub-Saharan African + Francophone Africa medicines QC capacity.
• PAHO + WHO Collaborating Centre — LNCM serves as WHO Collaborating Centre for pharmaceutical analytical training + capacity-building.
• Vaccine lot release — LNCM conducts vaccine lot-release testing for DMP + Moroccan PNI + selected African vaccine programmes.
• Pharmaceutical pre-registration + post-market testing — LNCM conducts pre-registration quality testing + post-market surveillance + targeted enforcement testing for DMP.
• Counterfeit-medicine forensics — LNCM provides forensic analytical support for DMP + Direction Générale de la Sûreté Nationale (DGSN) + Direction Générale des Douanes investigations + WHO Global Surveillance & Monitoring System contributions.
• Capacity-building — LNCM hosts AMRH + AMA + Union for the Mediterranean + Council of Arab Ministers of Health capacity-building programmes + training for African + Mediterranean + Arab pharmaceutical analysts.
• GMP Inspectorate support — LNCM provides scientific + technical support for DMP GMP inspections of Moroccan + foreign manufacturing facilities.
• Moroccan Pharmacopoeia development — LNCM contributes to Moroccan Pharmacopoeia monograph development alongside European + International Pharmacopoeia harmonisation.

DMP medical-device + IVD regulation operates under Law 84-12 of 17 January 2014 with Class I-III risk-based framework substantively aligned with EU MDR predecessor (Directive 93/42/EEC era at adoption, progressively updated) + GHTF/IMDRF + AMRH-MDH. Foreign manufacturers must appoint a Moroccan Authorised Representative (Représentant Autorisé).

• Risk-based Classification (Class I / IIa / IIb / III) — substantively aligned with EU MDR predecessor + GHTF/IMDRF + AMRH-MDH; IVDs classified under separate Moroccan IVD framework.
• Représentant Autorisé Marocain — Morocco-resident legal entity required for foreign manufacturers; bears post-market matériovigilance responsibility + DMP regulatory interface.
• ISO 13485:2016 — recognised by DMP as QMS evidence framework; Moroccan-specific overlay required including Moroccan quality records + Représentant Autorisé QMS interface.
• Reliance pathways — DMP accepts CE Mark + FDA 510(k) + Health Canada + TGA + Swissmedic + MFDS + Japan-approval evidence as supporting evidence under reliance framework; reliance reduces dossier + accelerates review; CE Mark particularly central given francophone + EU regulatory tradition.
• AMRH Medical Devices Harmonisation — DMP participates in AMRH-MDH work-streams; reliance + harmonised technical-file requirements progressively expanding across African Member States.
• Union for the Mediterranean Medical-Device Cooperation — DMP participates in UfM medical-device regulatory cooperation alongside EU Mediterranean Member States + Mediterranean Partner Countries.
• Post-market matériovigilance — DMP operates medical-device adverse-event reporting through the Moroccan Matériovigilance System coordinated by CAPM; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• Cosmetic Notification — cosmetics under Law 65-00 require Cosmetic Notification + French + Arabic labelling; INCI-aligned ingredient listing + safety substantiation + cosmétovigilance reporting; substantively EU-aligned framework.
• Moroccan UDI — DMP is progressively implementing UDI requirements substantively aligned with FDA UDI + EU EUDAMED UDI; Moroccan-specific overlay applies.
• Importation Permit — DMP Importation Permit required in addition to product registration for foreign-manufactured devices entering Morocco; coordination with Direction Générale des Douanes.

DMP operates the Moroccan Pharmacovigilance Programme through coordination with CAPM (Centre Anti-Poison et de Pharmacovigilance du Maroc) in Rabat. Morocco is a long-standing WHO Programme for International Drug Monitoring (PIDM) member (since 1992) + contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre (UMC). CAPM operates Morocco's combined pharmacovigilance + toxicovigilance + anti-poison centre — an integrated model providing efficient resource use.

• Centre Anti-Poison et de Pharmacovigilance du Maroc (CAPM) — Rabat-based integrated pharmacovigilance + toxicovigilance + anti-poison centre operating under DMP coordination; integrated model provides efficient resource use across pharmacovigilance + toxicovigilance + clinical-toxicology + anti-poison-information functions.
• WHO PIDM Long-standing Member — Morocco is a long-standing WHO PIDM member (since 1992) + contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre.
• Réseau Marocain de Pharmacovigilance — coordinated national pharmacovigilance network with effector centres in major university hospitals (CHU Ibn Sina Rabat, CHU Ibn Rochd Casablanca, CHU Hassan II Fès, CHU Mohammed VI Marrakech, CHU Mohammed VI Oujda, CHU Hassan II Agadir, CHU Tanger) + Direction Régionale de la Santé + Marketing Authorisation Holders.
• Online ADR Reporting — DMP/CAPM operates online ADR reporting via the CAPM portal; available for healthcare professionals + consumers + Marketing Authorisation Holders.
• E2B(R3) ICSR — DMP accepts E2B(R3) format ICSR submissions substantively aligned with ICH E2B(R3); 15-day SUSAR reporting timeline for clinical trials + post-market.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2); DMP-specific submission timeline.
• Risk Management Plans (RMP) — DMP requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + high-risk products.
• Active surveillance — DMP/CAPM operates targeted active-surveillance programmes including for HIV antiretrovirals + tuberculosis + COVID-19 vaccines + biologicals + sentinel-site hospital surveillance through major Moroccan CHUs.
• Manifestations Postvaccinales Indésirables (MAPI) — Moroccan vaccine adverse-event surveillance aligned with WHO methodology; central to PNI + COVID-19 vaccine safety monitoring.
• Matériovigilance + Cosmétovigilance + Réactovigilance — DMP/CAPM operates parallel matériovigilance for medical devices + cosmétovigilance for cosmetics + réactovigilance for IVDs.

• WHO Listed Authority Candidate — DMP is a WHO Listed Authority candidate based on active WHO PQ CRP participation + LNCM WHO PQ-Lab status + AMRH co-Reference Authority designation.
• WHO PQ CRP Participating Authority — DMP is an active WHO Prequalification Collaborative Registration Procedure (CRP) participating authority.
• WHO PQ-Lab — LNCM is a WHO-prequalified pharmaceutical QC laboratory since 2016; one of few in Africa + the Mediterranean basin.
• AMRH co-Reference Authority — DMP is an active AMRH (African Medicines Regulatory Harmonisation) co-Reference Authority alongside SAHPRA + Ghana FDA + Kenya PPB + Tanzania TMDA + Uganda NDA + Rwanda FDA + Nigeria NAFDAC + Egyptian EDA + Ethiopia EFDA.
• AMA Technical Committee Participant — DMP participates in African Medicines Agency (AMA) Technical Committees under AU Decision Assembly/AU/Dec.857(XXXVII) + Kigali HQ coordination; positioned to provide reliance assessments for AMA-coordinated submissions.
• Union for the Mediterranean (UfM) Partner — DMP participates in UfM regulatory cooperation alongside EU Mediterranean Member States (France, Spain, Italy, Portugal, Greece, Cyprus, Malta) + Mediterranean Partner Countries (Algeria, Tunisia, Egypt, Israel, Jordan, Lebanon, Palestine, Turkey).
• League of Arab States Council of Arab Ministers of Health — active pharmaceutical-harmonisation participant alongside Egyptian EDA + Saudi SFDA + Tunisian ANPM + Algerian ANPP + Jordanian JFDA + UAE MoHAP + Lebanese MoH + Kuwait MoH + Bahrain NHRA + others; supports Arab League pharmaceutical-policy coordination.
• EMA Working Arrangement — DMP holds Working Arrangement with EMA covering information exchange + reliance + capacity-building; reflects Morocco's francophone + EU-aligned regulatory tradition.
• ANSM France Bilateral — DMP holds substantial bilateral cooperation with ANSM France reflecting historic Franco-Moroccan ties + francophone regulatory alignment; ANSM France provides training + scientific cooperation.
• AEMPS Spain + AIFA Italy + PEI Germany Bilateral — DMP holds bilateral cooperation with AEMPS Spain + AIFA Italy + PEI Germany reflecting Mediterranean + EU regulatory cooperation.
• ICH Observer Candidate — DMP is positioned for ICH Observer status; ICH guidelines extensively implemented in Moroccan regulatory practice including ICH Q7 + Q8 + Q9 + Q10 + Q11 + E2A-E + M4.
• IMDRF Affiliate Candidate — DMP is positioned for IMDRF Affiliate status + draws on IMDRF guidance for medical-device regulation.
• PIC/S Pre-Accession Pathway — DMP is on PIC/S Pre-Accession pathway; BPF framework substantively aligned with PIC/S GMP Guide + EU GMP + ICH Q7.
• Maghreb Pharmaceutical Cooperation — DMP participates in Arab Maghreb Union (UMA) pharmaceutical cooperation alongside Algeria ANPP + Tunisia ANPM + Libya NRA + Mauritania DPL; though UMA broadly dormant since 1994 closure of Morocco-Algeria border, pharmaceutical-cooperation channels remain.
• ICDRA + AVAREF participation — active International Conference of Drug Regulatory Authorities + African Vaccine Regulatory Forum (AVAREF) participant.

• Moroccan Représentant Autorisé not properly designated — application rejected at DMP intake or post-approval compliance failure.
• French + Arabic labelling deficiencies — French + Arabic labelling required (with selective Amazigh/Tamazight Constitutional co-official inclusion); many applicants provide insufficient Arabic-language Patient Information Leaflet (notice patient) or use European French rather than Moroccan French terminology.
• BPF gaps — applicants assuming EU GMP / PIC/S GMP compliance is automatically sufficient without addressing Morocco-specific DMP BPF clarifications + Moroccan quality records.
• Moroccan climate-zone stability data missing — Morocco spans Climate Zone II (Atlantic + Mediterranean coastal) + Climate Zone III (interior + pre-Saharan + Sahara) + high-altitude Atlas Mountains; many applicants provide insufficient zonal-specific stability data particularly for pre-Saharan + Sahara distribution.
• Bioequivalence centres + biowaiver — DMP Biowaiver Guidance provides BCS-based biowaivers + applicants frequently submit BE studies where biowaivers would suffice; alternatively many submit insufficient BE evidence where studies are required.
• WHO PQ CRP reliance under-utilised — WHO-PQ-approved products eligible for accelerated DMP CRP review (90-day target); under-utilised by many applicants.
• AMRH / AMA reliance not leveraged — AMRH co-Reference Authority + AMA Technical Committee reliance pathways under-utilised; provides substantial acceleration for African-Reference-Authority-assessed products.
• EMA / ANSM France / AEMPS Spain reliance under-utilised — DMP operates strong reliance on EMA + ANSM France + AEMPS Spain + AIFA Italy + PEI Germany decisions reflecting Morocco's francophone + Mediterranean alignment; under-utilised by many applicants.
• Arab League harmonisation not leveraged — Council of Arab Ministers of Health pharmaceutical-harmonisation reliance under-utilised for Arab-Reference-Authority-assessed products (Egypt EDA, Saudi SFDA, Tunisian ANPM, Jordanian JFDA).
• Vital + Essential Medicines accelerated pathway not leveraged — accelerated AMM for Liste des Médicaments Essentiels + AMO-procurement-priority products under-utilised; 90-120 working day target.
• ONSSA jurisdictional split — veterinary medicines + animal-origin foods + food safety sit with ONSSA (Office National de Sécurité Sanitaire des produits Alimentaires), not DMP; avoid filing veterinary or food applications to DMP.
• Ministry-Directorate institutional position — DMP's Ministry-of-Health Directorate-level status (versus autonomous-agency status of most peer regulators including ISP + ANMAT + ANVISA + COFEPRIS + EDA + SAHPRA) means fee-retention is limited + direct Ministerial accountability shapes decision-making + Ministerial-priority-product treatment can affect timelines.
• Variations strategy not planned — variations procedure substantively similar to EU but with Morocco-specific timelines + fee structure + French/Arabic-language requirements.
• AMM renewal timing missed — 5-year AMM renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration + market withdrawal.
• Clinical trial CERB + Decree 2-12-198 steps — Moroccan clinical trials require DMP Autorisation d'Essai Clinique + Comité d'Éthique pour la Recherche Biomédique (CERB) approval; sponsors sometimes overlook CERB recognition + multi-CHU clinical-trial coordination + community-engagement requirements.
• Pharmacovigilance + CAPM gaps — DMP BPPv requirements substantively similar to ICH E2 + EU GVP but with Morocco-specific CAPM integrated pharmacovigilance + toxicovigilance + anti-poison centre coordination + French + Arabic ICSR.

V5 Ultimate provides the operational infrastructure Moroccan + foreign-supplier sites need for Dahir 1-58-295 of 1959 + Law 17-04 of 2006 + DMP BPF + DMP Medical Devices framework + AMRH + AMA + Union for the Mediterranean + Arab League + WHO PQ CRP + Moroccan Pharmacovigilance Programme readiness.

• DMP BPF control framework — PIC/S + EU GMP + ICH Q7-aligned controls (clean rooms, aseptic process, environmental monitoring, computerised systems) with ALCOA+ data-integrity + Morocco-specific clarifications + Moroccan climate-zone II/III + Atlas Mountains high-altitude stability monitoring.
• DMP AMM dossier packaging — Moroccan CTD-aligned dossier structure with Morocco Module 1 specifics + Module 3 stability + French + Arabic notice patient + Représentant Autorisé declarations + Law 17-04 framework.
• AMRH / AMA workflow — AMRH co-Reference Authority + AMA Technical Committee packaging for joint assessment + reliance across African Member States.
• WHO PQ CRP workflow — DMP-as-CRP-participating-authority packaging with reduced dossier + accelerated DMP review (90-day target).
• EU / EMA / ANSM France reliance workflow — Working Arrangement + ANSM France bilateral cooperation packaging reflecting Morocco's francophone + Mediterranean alignment.
• Union for the Mediterranean workflow — UfM regulatory cooperation packaging alongside EU Mediterranean Member States + Mediterranean Partner Countries.
• Arab League workflow — Council of Arab Ministers of Health pharmaceutical-harmonisation packaging with Egyptian EDA + Saudi SFDA + Tunisian ANPM + Algerian ANPP + Jordanian JFDA + UAE MoHAP coordination.
• Vital + Essential Medicines accelerated workflow — Liste des Médicaments Essentiels + AMO-procurement-priority product packaging with 90-120 working day accelerated review.
• Moroccan Représentant Autorisé workflow — foreign-manufacturer Représentant Autorisé designation + role-management + Morocco-specific post-market surveillance + DMP interface.
• Moroccan clinical-trial workflow — DMP Autorisation d'Essai Clinique + CERB + multi-CHU coordination + Moroccan SUSAR reporting via CAPM + community-engagement.
• DMP/CAPM Pharmacovigilance integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + French + Arabic ICSR + Réseau Marocain de Pharmacovigilance coordination + CAPM portal submission + VigiBase upload + Risk Management Plan packaging + MAPI vaccine adverse-event reporting.
• Matériovigilance + Cosmétovigilance + Réactovigilance workflow — parallel matériovigilance + cosmétovigilance + IVD-vigilance packaging coordinated through CAPM.
• Medical-device + cosmetic + IVD workflow — Law 84-12 of 2014 + Law 65-00 of 2002 dossier packaging + Class I-III classification + ISO 13485 + Représentant Autorisé + post-market matériovigilance.
• DMP AMM Variations workflow — variations classification + DMP procedure + Moroccan packaging.
• AMM Renewal workflow — 5-year AMM renewal window tracking + DMP procedure packaging.
• AMRH + AMA + UfM + Arab League regional bridging — for companies operating across Africa + the Mediterranean + the Arab World, V5 surfaces DMP + Egyptian EDA + Saudi SFDA + Tunisian ANPM + Algerian ANPP + Jordanian JFDA + UAE MoHAP + SAHPRA + Ghana FDA + Kenya PPB + Tanzania TMDA + Uganda NDA + Rwanda FDA + Nigeria NAFDAC + Ethiopia EFDA harmonised dossier-element reuse alongside national-specific extensions.